CA-ANOMALI
1.8.2022 11:02:08 CEST | Business Wire | Press release
Anomali , a leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions, today announced that Steve Benton has been appointed to the position of Vice President of Anomali Threat Research (ATR) and General Manager of the Anomali Belfast, Ireland Office. Benton, an experienced cyber security expert has a history of strategic advisory, intelligence sharing and coordinated response across MD, CxO, and board audiences. Benton joins Anomali during a time of rapid global expansion, to deliver guidance to global organizations on investment, strategy and making security a business enabler to rapidly address the evolving global threats of today and in the future.
“Steve brings a wealth of experience to Anomali – both in cybersecurity and in building and contributing to the wider security community. His experience and expertise spanning cyber security advisory, thought leadership, strategic development and execution will be a tremendous asset to our customers, partners, and investors,” said Mark Alba, CPO. “Steve’s extensive experience and expertise has been instrumental in helping guide global organizations on what is required to operate successfully in an ever-increasing and complex threat environment. We are very excited about Steve playing a pivotal role in how Anomali solutions can further help customers to thrive, grow and face security challenges with confidence.”
Benton has more than three decades of experience working with customers to solve their most difficult security challenges. Most recently, Benton was Deputy CISO and latterly CSO for BT where he was accountable for physical and cyber security across investment, posture, and response globally. While at BT, he built and led the Protect BT Services and Operations organization spanning intelligence, offensive security, cyber security operations, physical security operations, strategy, investigations, and incidents. In addition, he innovated proactive threat hunting and wide-ranging intelligence operations to anticipate threats, track threat actors, and their methods. An industry security expert, Benton is a contributing member of the Cyber Defenders Council, Fellow of the Chartered Institute of Information Security and a regular speaker and influencer to the i4 C level community.
“I am excited to join Anomali, the leader of threat-intelligence driven solutions, and contribute to the mission of helping organizations efficiently and effectively stop breaches and advanced adversaries,” said Benton. “As a previous customer, I leveraged the Anomali portfolio at the heart of my drive to improve security posture and disrupt threat actor activities at pace, whilst driving the democratisation of threat intelligence across the business. To know yourself and your adversaries through high fidelity, actionable intelligence, that constantly informs your decisions and guides a dynamic security posture, is the new battleground. And I look forward to bringing my frontline operational and strategic experience to Anomali customers and partners. With cyberattacks on the rise, ever more complex and multidimensional, organizations require an integrated XDR solution to tell them who they are up against, why, when they are being attacked, and how to accelerate their multifaceted response. The Anomali Platform greatly enhances an organization’s ability to address newly detected attacks, cresting threats and subsequent future attacks. Put simply, confidence in the face of uncertainty.”
For more information, visit:
www.anomali.com
Twitter: https://twitter.com/Anomali
LinkedIn: https://www.linkedin.com/company/anomali/
Blog: https://www.anomali.com/blog
About Anomali
Anomali is the leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions. Anchored by big data management (the “X”) and refined by artificial intelligence, The Anomali Platform, an XDR solution, delivers unique proprietary capabilities that correlate the largest repository of global intelligence with telemetry from customer-deployed security solutions. This combination empowers security operations teams to detect threats with precision, optimize response, achieve resiliency, and ultimately stop attackers and breaches. Our SaaS-based solutions easily integrate into existing security tech stacks through native-cloud, multi-cloud, on-premises, and hybrid deployments. Founded in 2013, Anomali serves global B2B enterprise businesses and large public sector organizations, ISACs, ISAOs, service providers, and Global 1000 customers to help safeguard the world’s critical infrastructure, businesses, and people. Leading venture firms, including Google Ventures, General Catalyst, and IVP, back Anomali.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220729005511/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
